CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, ShermanSI, TuttleRM. 2006. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109–142.
2.
CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
3.
KloosRT, EngC, EvansDB, FrancisGL, GagelRF, GharibH, MoleyJF, PaciniF, RingelMD, SchlumbergerM, WellsSAJr. 2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19:565–612.
4.
PaciniF, SchlumbergerM, DralleH, EliseiR, SmitJW, WiersingaW. 2006. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154:787–803.
5.
LusterM, ClarkeSE, DietleinM, LassmannM, LindP, OyenWJ, TennvallJ, BombardieriE. 2008. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 35:1941–1959.
6.
British Thyroid Association, Royal College of Physicians. 2007. Guidelines for the management of thyroid cancer, 2nd editionwww.british-thyroid-association.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf. 2009 September 20.
7.
WatkinsonJC. 2004. The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl Med Commun, 25:897–900.
8.
JemalA, SiegelR, WardE, HaoY, XuJ, ThunMJ. 2009. Cancer statistics, 2009. CA Cancer J Clin, 59:225–249.
9.
DaviesL, WelchHG. 2006. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 295:2164–2167.
10.
EnewoldL, ZhuK, RonE, MarrogiAJ, StojadinovicA, PeoplesGE, DevesaSS. 2009. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev, 18:784–791.
11.
Rego-IraetaA, Perez-MendezLF, MantinanB, Garcia-MayorRV. 2009. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid, 19:333–340.
12.
ChenAY, JemalA, WardEM. 2009. Increasing incidence of differentiated thyroid cancer in the United States 1988–2005. Cancer, 115:3801–3807.
13.
CheungK, RomanSA, WangTS, WalkerHD, SosaJA. 2008. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost effectiveness and decision analysis. J Clin Endocrinol Metab, 93:2173–2180.
14.
RinkT, TruongP-N, SchrothH-J, DienerJ, ZimnyM, GrunwaldF. 2009. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid, 19:327–332.
15.
AbrahamD, GaultPM, HuntJ, BentzJ. 2009. Calcitonin estimation in neck lymph node fine-needle aspirate fluid prevents misinterpretation of cytology in patients with metastatic medullary thyroid cancer. Thyroid, 19:1015–1016.
16.
BoiF, MaurelliI, PinnaG, AtzeniF, PigaM, LaiML, MariottiS. 2007. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab, 92:2115–2118.
17.
MazzaferriEL, SiposJ. 2008. Should all patients with subcentimeter thyroid nodules undergo fine-needle aspiration biopsy and preoperative neck ultrasonography to define the extent of tumor invasion?Thyroid, 18:597–602.
18.
XingM, ClarkDP, GuanH, JiM, DackiwAPB, CarsonKA, KimM, TufaroAP, LadensonPW, ZeigerMA, TufanoRP. 2009. BRAF mutation testing of thyroid fine needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol, 27:2977–2982.
19.
BentzBG, MillerBT, HoldenJA, RoweLR, BentzJS. 2009. B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. Otolaryngol Head Neck Surg, 140:708–714.
20.
NikiforovYE, StewardDL, Robinson-SmithTM, HaugenBR, KlopperJP, ZhuZ, FaginJA, FalcigliaM, WeberK, NikiforovaMN. 2009. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab, 94:2092–2098.
21.
American Joint Committee on Cancer. 2002. Cancer Staging Manual, 6th edition. Springer-Verlag: New York.
PilliT, BrianzoniE, CapoccettiF, CastagnaMG, FattoriS, PoggiuA, RossiG, FerrettiF, GuarinoE, BurroniL, VattimoA, CipriC, PaciniF. 2007. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab, 92:3542–3546.
24.
RosarioPW, BorgesMA, PurischS. 2008. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med, 49:1776–1782.
25.
RemyH, BorgetI, LeboulleuxS, GuilabertN, LavielleF, GarsiJ, BournaudC, GuptaS, SchlumbergerM, RicardM. 2008. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med, 49:1445–1450.
26.
Van NostrandD, AikenM, AtkinsF, MoreauS, GarciaC, AcioE, BurmanK, WartofskyL. 2009. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid, 19:849–585.
27.
McDougallIR. 2009. The case for obtaining a diagnostic whole-body scan prior to Iodine 131 treatment of differentiated thyroid cancer. Thyroid, 19:811–813.
28.
ShakirMK, KrookLS, SchramlFV, HaysJH, ClydePW. 2008. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma. Thyroid, 18:787–792.
29.
WartofskyL, ShermanSI, GopalJ, SchlumbergerM, HayID. 1998. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 83:4195–4203.
30.
KulkarniK, NostrandDV, AtkinsF, AikenM, BurmanK, WartofskyL. 2006. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid, 16:1019–1023.
31.
TuttleRM, LeboeufR, RobbinsRJ, QualeyR, PentlowK, LarsonSM, ChanCY. 2006. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med, 47:1587–1591.
32.
NakadaK, IshibashiT, TakeiT, HirataK, ShinoharaK, KatohS, ZhaoS, TamakiN, NoguchiY, NoguchiS. 2005. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?J Nucl Med, 46:261–266.
33.
Van NostrandD, AtkinsF, BandaruVV, ChennupatiSP, MoreauS, BurmanK, WartofskyL. 2009. Salivary gland protection with sialagogues: a case study. Thyroid, 19:1005–1008.
34.
KloosRT. 2009. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid, 19:925–928.
